CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 172 enrolled
Drug / intervention
Tiragolumab +1 moredrug
Likely dose
Tiragolumab 600 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04300647
NCT04300647Phase 2Completed
CompareCT.gov

A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Hoffmann-La Roche·interventional·Posted Mar 9, 2020·Updated Mar 12, 2026

In Brief

A Phase 2 clinical trial evaluating Tiragolumab and Atezolizumab for Cervical Cancer. Completed, enrolled 172 participants across 58 sites in 17 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in patients with programmed death-ligand 1 (PD-L1)-positive cervical cancer (metastatic and/or recurrent).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesAustralia, Brazil, Canada, Costa Rica, France, Italy, Mexico, Panama, Peru, Poland, Russia, South Korea, Spain, Taiwan, Thailand, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 9, 2020
Enrollment StartJun 30, 2020
Primary CompletionDec 8, 2021
Study CompletionFeb 24, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.3 years ago

Interventions

Tiragolumabdrug

Tiragolumab at a fixed dose of 600 milligrams (mg) will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Atezolizumabdrug

Atezolizumab at a fixed dose of 1200 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.